BMS Wants to Jolt Cancer Care Landscape with Broader I/O Combo Options, Pursuing LAG-3 Inhibitor in Japan Too

Yoshihide Oba, Head of Oncology Business Unit, BMS Japan Back in March, the US FDA approved a new type of immune checkpoint inhibitor, relatlimab, developed by Bristol Myers Squibb. Called a LAG-3-blocking antibody, the drug gained the nod as a...read more